Mirum Pharmaceuticals Inc (MIRM) 뉴스

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim...

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2024 financial results on August 7, 2024. Mirum...

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2024, the Compensation Committee of Mirum’s Board of Directors...

Approbation du LIVMARLI de Mirum Pharmaceuticals dans l'Union européenne pour les patients atteints de PFIC

La Commission européenne accorde une autorisation de mise sur le marché au LIVMARLI pour le traitement de la PFIC chez les patients âgés de...

LIVMARLI von Mirum Pharmaceuticals wird in der Europäischen Union für Patienten mit PFIC zugelassen

Die Europäische Kommission erteilt LIVMARLI die Marktzulassung für die Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten. Die...

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive...

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only...

Form 8-K - Current report

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of...

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on June 10, 2024, the Compensation Committee of Mirum’s Board of Directors...

Form 4 - Statement of changes in beneficial ownership of securities